Dr. Dave Anderson, Chief Scientific Officer at VBI Vaccines discusses the company’s work to develop a pan-coronavirus vaccine to address mutations. He talks about the public health implications of a mutation of COVID-19. In addition to COVID, VBI Vaccines is in late-stage development of the only potential vaccine that mimics all three surface antigens of the hepatitis B virus.
Dave Anderson, Chief Scientific Officer, VBI Vaccines. A dynamic and well-published immunologist with broad expertise in the areas of vaccine development, autoimmunity and tumor immunology, Dr. Anderson joined VBI full time in 2009 from Harvard Medical School, where he held a position as Assistant Professor. As a co-founder and Chief Scientific Officer of VBI, Dr. Anderson is an inventor of much of the Company’s intellectual property and actively manages its ongoing expansion. Dr. Anderson holds a Ph.D. from Harvard University and a B.S. from the University of California at Davis.